SHPMY: AI 评分 40/100 — AI 分析 (4月 2026)

Shanghai Pharmaceuticals Holding Co., Ltd. is a leading Chinese pharmaceutical company involved in the research, development, manufacturing, distribution, and retail of pharmaceutical and healthcare products. With a broad portfolio and extensive distribution network, the company plays a significant role in China's healthcare industry.

Key Facts: AI Score: 40/100 Sector: Healthcare

公司概况

概要：

Shanghai Pharmaceuticals Holding Co., Ltd., a major player in the Chinese pharmaceutical sector, focuses on the entire value chain from R&D and manufacturing to distribution and retail. With a diverse product portfolio and a wide network of retail pharmacies, it addresses key therapeutic areas while navigating the evolving healthcare landscape in China.

SHPMY是做什么的？

Shanghai Pharmaceuticals Holding Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, China. As an investment holding company and a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., it operates across four segments: Production, Distribution, Retail, and Others. The Production segment focuses on manufacturing a diverse range of pharmaceutical products, including chemicals, biochemicals, Chinese medicines, healthcare products, and medical devices. These products target therapeutic areas such as oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. The Distribution segment provides pharmaceutical distribution, warehousing, and logistics services to manufacturers, hospitals, distributors, and retail pharmacies. The Retail segment operates a network of approximately 2,000 retail chain pharmacies across 24 provinces, along with an online drug business. The company also offers consulting services, asset management, clinical trials, medical aid, physician education, e-prescription management, and remote hospital services. Shanghai Pharmaceuticals Holding Co., Ltd. plays a critical role in the Chinese healthcare ecosystem, providing a comprehensive suite of products and services.

SHPMY的投资论点是什么？

Shanghai Pharmaceuticals Holding Co., Ltd. presents a compelling investment case based on its integrated business model and strong market position in China. The company's diverse product portfolio and extensive distribution network provide a stable revenue base. With a P/E ratio of 11.36 and a dividend yield of 2.37%, the stock offers potential value and income. Growth catalysts include expanding its retail pharmacy network and increasing its focus on innovative drugs. However, the may be worth researching regulatory risks and competitive pressures in the Chinese pharmaceutical market, as well as the impact of currency fluctuations on its ADR.

SHPMY在哪个行业运营？

Shanghai Pharmaceuticals Holding Co., Ltd. operates in the rapidly growing Chinese pharmaceutical market. The industry is driven by increasing healthcare spending, an aging population, and rising chronic disease prevalence. The company competes with other major pharmaceutical distributors and manufacturers, including CNVVF (China National Medicines Corporation Ltd), CNVVY (Sinopharm Group Co Ltd), DSRLF (D S Healthcare Holdings Ltd), GNGBY (Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd), and GZPHF (Guangzhou Pharmaceutical Co Ltd). Regulatory changes and pricing pressures pose ongoing challenges, but also create opportunities for companies with strong distribution networks and innovative product pipelines.

Medical - Distribution

Healthcare

SHPMY有哪些增长机遇？

Expansion of Retail Pharmacy Network: Shanghai Pharmaceuticals can grow by expanding its network of retail pharmacies across China. With approximately 2,000 retail chain pharmacies currently, there is potential to increase market share by penetrating underserved regions and offering value-added services like telemedicine and chronic disease management. The Chinese retail pharmacy market is projected to reach $300 billion by 2028, presenting a significant opportunity for growth.
Development of Innovative Drugs: Investing in research and development to create innovative drugs can drive long-term growth. Focusing on high-demand therapeutic areas like oncology and CNS disorders can lead to higher-margin products and increased market share. The global market for innovative drugs is expected to reach $1.2 trillion by 2030, offering substantial revenue potential.
Strengthening Distribution Network: Optimizing and expanding its pharmaceutical distribution network can improve efficiency and reach. Investing in advanced logistics and supply chain technologies can reduce costs and enhance service quality. The Chinese pharmaceutical distribution market is expected to grow at a CAGR of 8% over the next five years, driven by increasing demand for pharmaceuticals.
Online Drug Business Expansion: Growing its online drug business can tap into the increasing trend of online healthcare and e-commerce. Offering a wider range of products and services online, along with convenient delivery options, can attract new customers and increase sales. The online pharmacy market in China is projected to reach $100 billion by 2027, presenting a significant growth opportunity.
Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies and acquiring smaller players can expand its product portfolio and market reach. Collaborating with international companies can also provide access to new technologies and markets. The pharmaceutical industry is witnessing increasing consolidation, and strategic alliances can enhance competitiveness.

Market capitalization of $5.64 billion, reflecting its significant presence in the Chinese pharmaceutical market.
P/E ratio of 11.36, suggesting a potentially undervalued stock compared to its earnings.
Profit margin of 2.0%, indicating room for improvement in operational efficiency.
Gross margin of 10.6%, highlighting the need to optimize production and distribution costs.
Dividend yield of 2.37%, providing a steady income stream for investors.

SHPMY提供哪些产品和服务？

Researches and develops pharmaceutical products.
Manufactures a wide range of drugs and healthcare products.
Distributes pharmaceutical products to hospitals, distributors, and retail pharmacies.
Operates a network of approximately 2,000 retail chain pharmacies.
Provides pharmaceutical supply chain solutions and related services.
Engages in online drug business.
Offers consulting services and asset management operations.
Conducts clinical trials and provides medical aid.

SHPMY如何赚钱？

Generates revenue from the sale of manufactured pharmaceutical products.
Earns fees from providing pharmaceutical distribution and logistics services.
Derives income from retail sales through its pharmacy network.
Receives revenue from online drug sales.
Provides consulting and asset management services for additional income.

Hospitals and healthcare institutions.
Pharmaceutical distributors and wholesalers.
Retail pharmacies.
Individual consumers through retail pharmacies and online channels.
Pharmaceutical manufacturers.

Extensive Distribution Network: Its widespread distribution network provides a significant competitive advantage in reaching customers across China.
Diverse Product Portfolio: A broad range of pharmaceutical products reduces reliance on any single product and caters to various therapeutic areas.
Established Brand Reputation: A long history and established brand name in the Chinese pharmaceutical market provide trust and recognition.
Integrated Business Model: Its integrated model, covering R&D, manufacturing, distribution, and retail, provides greater control and efficiency.

什么因素可能推动SHPMY股价上涨？

Upcoming: Potential regulatory approvals for new drugs in the pipeline.
Ongoing: Expansion of the retail pharmacy network across China.
Ongoing: Increasing demand for pharmaceutical products due to an aging population.
Ongoing: Growth in the online drug business and e-commerce trends.

SHPMY的主要风险是什么？

Potential: Regulatory changes and pricing pressures in the Chinese pharmaceutical market.
Potential: Currency fluctuations impacting ADR value.
Potential: Increasing competition from domestic and international players.
Ongoing: Supply chain disruptions affecting manufacturing and distribution.
Ongoing: Dependence on the Chinese market.

SHPMY的核心优势是什么？

Integrated business model covering R&D, manufacturing, distribution, and retail.
Extensive distribution network across China.
Diverse product portfolio catering to various therapeutic areas.
Established brand reputation in the Chinese pharmaceutical market.

SHPMY的劣势是什么？

Relatively low profit margin compared to global peers.
Dependence on the Chinese market.
Exposure to regulatory changes and pricing pressures.
Limited international presence.

SHPMY有哪些机遇？

Expanding retail pharmacy network in underserved regions.
Investing in research and development of innovative drugs.
Growing online drug business to tap into e-commerce trends.
Forming strategic partnerships and acquisitions to expand market reach.

SHPMY面临哪些威胁？

Increasing competition from domestic and international players.
Regulatory changes and pricing pressures affecting profitability.
Currency fluctuations impacting ADR value.
Potential supply chain disruptions.

SHPMY的竞争对手是谁？

China National Medicines Corporation Ltd — A major pharmaceutical distributor in China. — (CNVVF)
Sinopharm Group Co Ltd — One of the largest pharmaceutical companies in China. — (CNVVY)
D S Healthcare Holdings Ltd — Focuses on pharmaceutical distribution and retail. — (DSRLF)
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd — Specializes in traditional Chinese medicines and pharmaceuticals. — (GNGBY)
Guangzhou Pharmaceutical Co Ltd — Engaged in pharmaceutical manufacturing and distribution. — (GZPHF)

Key Metrics

MoonshotScore: 40/100

Company Profile

CEO: Qiuhua Yang
Headquarters: Shanghai, CN
Employees: 49,402
Founded: 2014

AI Insight

AI analysis pending for SHPMY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: SHPM

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Shanghai Pharmaceuticals Holding Co., Ltd do?

Shanghai Pharmaceuticals Holding Co., Ltd. is a comprehensive pharmaceutical company that operates across the entire value chain, from research and development to manufacturing, distribution, and retail. It produces and distributes a wide range of pharmaceutical products, including chemicals, biochemicals, Chinese medicines, healthcare products, and medical devices. The company also operates a large network of retail pharmacies and provides pharmaceutical supply chain solutions. This integrated model allows it to capture value at multiple stages and maintain a strong presence in the Chinese healthcare market.

What do analysts say about SHPMY stock?

Analyst coverage of SHPMY is limited due to its OTC listing and ADR status. However, the company's financial performance and strategic initiatives are closely monitored. Key valuation metrics include its P/E ratio of 11.36 and dividend yield of 2.37%. Growth considerations include its expansion plans, R&D pipeline, and exposure to the Chinese pharmaceutical market. Investors should conduct their own research and consider their risk tolerance before investing.

What are the main risks for SHPMY?

The main risks for Shanghai Pharmaceuticals Holding Co., Ltd. include regulatory changes and pricing pressures in the Chinese pharmaceutical market, which can impact profitability. Currency fluctuations can also affect the value of its ADR for U.S. investors. Increasing competition from both domestic and international players poses a threat to its market share. Additionally, potential supply chain disruptions and its dependence on the Chinese market are ongoing concerns.